Related Experiment Videos
Sucralfate versus cimetidine in reflux esophagitis. A single-blind multicenter study
W Hameeteman1, D M v d Boomgaard, W Dekker
1Department of Gastro-enterology, Academic Medical Centre, Amsterdam, The Netherlands.
Journal of Clinical Gastroenterology
|August 1, 1987
Summary
Sucralfate and cimetidine both effectively treat reflux esophagitis symptoms. Sucralfate demonstrates comparable efficacy to cimetidine, offering a viable alternative for managing this condition.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Reflux esophagitis is a common gastrointestinal condition.
- Effective management strategies are crucial for patient outcomes.
Purpose of the Study:
- To compare the efficacy of sucralfate and cimetidine in treating reflux esophagitis.
- To evaluate symptomatic and endoscopic improvements in patients.
Main Methods:
- A single-blind, randomized, multicenter study involving 42 patients.
- Patients received either sucralfate (1g q.i.d.) or cimetidine (400mg q.i.d.) for 8 weeks.
- Symptomatic and endoscopic assessments were performed.
Main Results:
- Both treatments showed good symptomatic improvement, comparable between groups.
- Sucralfate led to esophagitis improvement in 53% and healing in 31%.
- Cimetidine showed improvement in 67% and healing in 14%; one cimetidine patient developed a stricture.
Conclusions:
- Sucralfate improves symptoms and reduces the severity of reflux esophagitis.
- Sucralfate is a valid alternative to H2-receptor antagonist therapy like cimetidine.
- Both treatments were well-tolerated with minimal side effects.